HIV surveillance among injecting drug users

被引:38
作者
Des Jarlais, DC
Dehne, K
Casabona, J
机构
[1] Beth Israel Deaconess Med Ctr, Inst Chem Dependency, Edmond Rothschild Fdn, New York, NY 10003 USA
[2] Heidelberg Univ, D-6900 Heidelberg, Germany
[3] Hosp Univ Germans Trian & Pujol, Ctr Estudis Epidemiol Catalunya, CEESCAT, Badalona 08916, Spain
关键词
HIV; AIDS; surveillance; injecting drug use; substance abuse; behavior;
D O I
10.1097/00002030-200104003-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Injecting drug users (IDUs) should be considered a 'partially hidden population' at high risk for HIV infection. In almost all locations it should be possible to locate and conduct research with IDUs, but it will probably never be possible to enumerate or draw random samples from an IDU population. Surveillance research studies with IDUs should include risk behaviors, as surveillance of HIV infection only will not be sufficiently time sensitive, and be used to develop and refine HIV prevention programming for the population. Contacts with IDUs can be developed at multiple settings, including voluntary treatment programs, law enforcement settings, and through 'street outreach.' Each type of setting has different advantages, disadvantages and ethical concerns. HIV testing as part of surveillance also raises additional important ethical concerns. The primary risk behaviors that should be included in surveillance studies are 'sharing' of drug injection equipment, the potential for rapid partner change among risk partners, and sexual risk behavior. Additional important objectives for surveillance research include: (1) the size of the local IDU population, (2) patterns of drug use, (3) availability injection equipment, (4) participation in prevention activities, and (5) access to and use of anti-retroviral treatments. HIV incidence is an ultimate objective for surveillance research, but there are no currently available cost-efficient methods for studying HIV incidence, so estimation from Introduction indirect measurements is usually required. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:S13 / S22
页数:10
相关论文
共 37 条
[1]  
ADELEKAN ML, 1998, GLOB RES NETW M HIV, P55
[2]  
[Anonymous], HDB RISK AIDS INJECT
[3]  
[Anonymous], AIDS WORLD
[4]  
Broadhead RS, 1999, PUBLIC HEALTH, V113, P42
[5]   HIV prevention in developed countries [J].
Coates, TJ ;
Aggleton, P ;
Gutzwiller, F ;
DesJarlais, D ;
Kihara, M ;
Kippax, S ;
Schechter, M ;
vandenHoek, JAR .
LANCET, 1996, 348 (9035) :1143-1148
[6]   The HIV AIDS epidemic in eastern Europe:: recent patterns and trends and their implications for policy-making [J].
Dehne, KL ;
Khodakevich, L ;
Hamers, FF ;
Schwartländer, B .
AIDS, 1999, 13 (07) :741-749
[7]  
DEHNE KL, 1999, UPDATE HIV EPIDEMIC
[8]   INTERNATIONAL EPIDEMIOLOGY OF HIV AND AIDS AMONG INJECTING DRUG-USERS [J].
DESJARLAIS, DC ;
FRIEDMAN, SR ;
CHOOPANYA, K ;
VANICHSENI, S ;
WARD, TP .
AIDS, 1992, 6 (10) :1053-1068
[9]   MAINTAINING LOW HIV SEROPREVALENCE IN POPULATIONS OF INJECTING DRUG-USERS [J].
DESJARLAIS, DC ;
HAGAN, H ;
FRIEDMAN, SR ;
FRIEDMANN, P ;
GOLDBERG, D ;
FRISCHER, M ;
GREEN, S ;
TUNVING, K ;
LJUNGBERG, B ;
WODAK, A ;
ROSS, M ;
PURCHASE, D ;
MILLSON, ME ;
MYERS, T .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (15) :1226-1231
[10]  
Domingo-Salvany A, 1998, AM J EPIDEMIOL, V148, P732